1-6 of 6
Jussi Koivunen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4334: Clever-1/PD-L1 ratio predicts response to Bexmarilimab, a novel macrophage-guided immunotherapy, in immune deprived cancers

Mari L. Björkman, Elisa M. Vuorinen, Juho Jalkanen, Marie-Louise Fjällskog, Jussi Koivunen, Teppo Huttunen, Maija Hollmén, Petri Bono
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4334.
https://doi.org/10.1158/1538-7445.AM2023-4334
Published: 04 April 2023
View article titled, Abstract 4334: Clever-1/PD-L1 ratio predicts response to Bexmarilimab, a novel macrophage-guided immunotherapy, in immune deprived cancers
Journal Articles

Abstract 2767: Low baseline serum IFNg and TNFa are predictive of response to bexmarilimab

Jussi Koivunen, Juho Jalkanen, Mari Björkman, Jami Mandelin, Petri Bono
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2767.
https://doi.org/10.1158/1538-7445.AM2022-2767
Published: 15 June 2022
View article titled, Abstract 2767: Low baseline serum IFNg and TNFa are predictive of response to bexmarilimab
Journal Articles

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

Takaaki Sasaki, Jussi Koivunen, Atsuko Ogino, Masahiko Yanagita, Sarah Nikiforow, Wei Zheng, Christopher Lathan, J. Paul Marcoux, Jinyan Du, Katsuhiro Okuda, Marzia Capelletti, Takeshi Shimamura, Dalia Ercan, Magda Stumpfova, Yun Xiao, Stanislawa Weremowicz, Mohit Butaney, Stephanie Heon, Keith Wilner, James G. Christensen, Michel J. Eck, Kwok-Kin Wong, Neal Lindeman, Nathanael S. Gray, Scott J. Rodig, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2011) 71 (18): 6051–6060.
https://doi.org/10.1158/0008-5472.CAN-11-1340
Published: 13 September 2011
View article titled, A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Open the PDF for A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

EML4-ALK fusion gene and sensitivity to an ALK kinase inhibitor in lung cancer

Jussi Koivunen, Craig Mermel, Kreshnik Zejnullahu, Carly Murphy, Alison Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Jinseon Lee, William Richards, David Sugarbaker, Christopher Ducko, Neal Lindeman, J. Paul Marcoux, Nathanael Gray, Charles Lee, Matthew Meyerson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2373.
Published: 01 May 2008
View article titled, EML4-ALK fusion gene and sensitivity to an ALK kinase inhibitor in lung cancer
Journal Articles

Disparate effects of gefitinib and lapatinib on egfr mutant lung cancer

Kreshnik Zejnullahu, Jussi Koivunen, Kimio Yonesaka, Caihong Yun, Jeffrey Swanson, Jeffrey Engelman, Bruce Johnson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3636.
Published: 01 May 2008
View article titled, Disparate effects of gefitinib and lapatinib on <em>egfr</em> mutant lung cancer
Journal Articles

Protein Kinase C α/β Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells

Jussi Koivunen, Vesa Aaltonen, Sanna Koskela, Petri Lehenkari, Matti Laato, Juha Peltonen
Journal: Cancer Research
Cancer Res (2004) 64 (16): 5693–5701.
https://doi.org/10.1158/0008-5472.CAN-03-3511
Published: 16 August 2004
View article titled, Protein Kinase C α/β Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells
Open the PDF for Protein Kinase C α/β Inhibitor Go6976 Promotes Formation of Cell Junctions and Inhibits Invasion of Urinary Bladder Carcinoma Cells in another window